The medicines whose prices have been reduced belong to therapeutic categories, like dexametozone, betamethazone, ampicillin and ranitidine. The prices of some multi-vitamins and antibiotics would rise a bit.
The R&D plan, focused on diseases affecting poor nations, is expected to be ready by 2008 and may benefit Indian drug firms and contract research organisations in a big way.
The PhRMA's observation is significant against the backdrop of Swiss pharma major Novartis AG's decision to relocate its R&D investments from India.
The patent department made this declaration on August 16 after Novartis had failed to respond to its queries within the prescribed time.
The profit margins of multinational companies importing medicines into India have been hit with the National Pharmaceutical Pricing Authority starting strict scrutiny of price approval applications for imported products.
Indian exporters of ayurvedic drugs are finding it extremely difficult to tap this high-growth segment
According to a petition filed by Quadrant in the Delhi High Court, Travel Guru allegedly copied its software solution 'Final Quadrant SuiteCase'.
Absence of operational manual that guides examiners, heavy backlog take a toll.
Indian pharmaceutical companies exporting medicines worth $1 billion to at least a dozen countries like Brazil, Mexico, China and Germany are finding non-tariff barriers, in the form of discriminatory treatments, hampering their export prospect.
Still drinks, nectars and packaged water sales are maturing quickly to grab a major share of the Indian beverages market, according to "The 2007 India Soft Drinks Report" by Canadean, the global beverages research company.
Dire warnings that the future wars will be fought over water may come true sooner than anticipated, albeit with a flavour. At least four behemoths, three of them multinationals, will soon mount an assault on the flavoured water market.
Besides Novartis, the other companies are Roche, J&J, Glaxo and Astrazeneca.
This has prompted public health groups to call the concerns of Swiss drug major Novartis that inadequacies in Indian patent law will have negative consequences for patients and public health in India as 'bogus'.
Having failed to receive even a lukewarm response to the open tender for marketing India as a tourist destination overseas, the ministry of tourism has decided to extend the deadline by over a fortnight to mid-August.
The central government is considering an expansion of the list of fertilisers that are eligible for subsidy.
Rs 35,000 crore investment to increase capacity by 75%.
Mohit Burman, the youngest among the newly appointed corporate heads among Dabur businesses, is known to have a penchant for acquisitions.
Interestingly, the allegations against Indian arm of the world's largest pharma maker also relates to its acquisition of the Indian subsidiary of Parke Davis by Pfizer in 2000.
Sources close to the development said this could happen at a meeting of the company's board of directors on Thursday.
Individual scientists attached to research institutions and domestic companies like Lupin, Dr Reddy's and Cadila account for the rest.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances